<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403702</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-0021</org_study_id>
    <nct_id>NCT00403702</nct_id>
  </id_info>
  <brief_title>Comparison High-Density Silicone Oils in Retinal Detachment</brief_title>
  <official_title>Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the safety, intraocular adverse effects and the
      anatomic and functional outcome with two endotamponade silicone oil after a 3-month in
      complex inferior retinal re-detachments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Five to 10% of retinal detachments progressed to proliferative vitreoretinopathy (PVR), the
      common more cause of surgical failure of retina detachment.

      Despite the use of internal tamponades, the treatment of retinal detachments due to a
      progressed proliferative vitreoretinopathy (PVR) is still a problem. At present, conventional
      silicone oil, having a lower specific gravity than water, is an excellent tool in advanced
      PVR retinal detachment especially of the upper circumference.

      In the past, to diminish the re-detachments diverse heavier-than-water density endotamponades
      were investigated by to use in in cases of inferior PVR. However,heavier-than-water density
      endotamponades have demonstrated adverse short term effects. (Example: silicon dispersion:
      hypotension and inflammation)

      Recently, two new long-term heavier-than-water internal tamponades were introduced: Oxane HD
      [oil-RMN3-mixture] and Densiron [mixture of 30.5 vol% perfluorohexyloctane (F6H8) with 69.5
      vol% polydimethylsiloxane (silicone oil)], showing satisfying anatomical results and good
      intraocular tolerance.

      In the present study, we will compare the anatomical outcome, functional results and
      intraocular adverse effects of two types of heavier tamponades.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">August 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>anatomical results</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>complication: hypotony,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vitreous hemorrhage,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammatory reaction,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cataract,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic hypotony,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP elevated intraocular pressure,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pseudohypopyon,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fibrin,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>emulsification droplets in the anterior chamber</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Retinal Detachment</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxane HD [oil-RMN3-mixture]</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Densiron [(F6H8)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients complicated persistent retinal detachment due secondary to proliferative
             vitreoretinopathy

        Exclusion Criteria:

          -  Diabetes

          -  Uveitis

          -  Glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Study Director</role>
    <affiliation>Asociación para Evitar la Ceguera en México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Luis Diaz-Rubio, MD</last_name>
    <phone>+52 (55) 10841400</phone>
    <phone_ext>1172</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asociacion Para Evitar la Ceguera en Mexico</name>
      <address>
        <city>Mexico</city>
        <state>D.F</state>
        <zip>04330</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yoko burgoa</last_name>
      <phone>+52 (55) 1084 1400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Mariana Martinez</last_name>
      <phone>+52 (55) 1084 1400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Luis Diaz-Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maximiliano Gordon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Kon-Jara</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitzy Torres</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Orlando Ustariz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerardo Garcia-Aguirre</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Sandner D, Engelmann K. First experiences with high-density silicone oil (Densiron) as an intraocular tamponade in complex retinal detachment. Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):609-19. Epub 2005 Oct 5.</citation>
    <PMID>16205937</PMID>
  </reference>
  <reference>
    <citation>Theelen T, Tilanus MA, Klevering BJ. Intraocular inflammation following endotamponade with high-density silicone oil. Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):617-20. Epub 2004 Mar 17.</citation>
    <PMID>15029505</PMID>
  </reference>
  <reference>
    <citation>Nicolai U, Eckardt C, Kohlhoff M, Wottge HU. Biocompatibility of silicone oil and high-density liquids. An immunologic study. Ger J Ophthalmol. 1992;1(3-4):180-7.</citation>
    <PMID>1483133</PMID>
  </reference>
  <reference>
    <citation>Mester U, Rothe R, Zubcov A. Experimental studies with a high-density silicone oil for giant retinal tear. Ophthalmic Res. 1986;18(2):81-6.</citation>
    <PMID>3737116</PMID>
  </reference>
  <reference>
    <citation>Wong D, Cazabon S, Ali H, Kumar I, Valldeperas X, Groenewald C, Pearce I. Can the sequential use of conventional silicone oil and heavy oil be a strategy for the management of proliferative vitreoretinopathy? Ann Acad Med Singapore. 2006 Mar;35(3):181-4.</citation>
    <PMID>16625267</PMID>
  </reference>
  <reference>
    <citation>Scheer S, Boni S, Barale PO, Bourhis A, Bonnel S, Tuil E, Girmens JF, Buil O, Baudouin C, Laroche L, Nordmann JP, Poisson F, Warnet JM, Sahel JA. [Heavy silicone oil as internal tamponade for retinal detachment: efficacy and tolerance]. J Fr Ophtalmol. 2006 Feb;29(2):129-35. French.</citation>
    <PMID>16523153</PMID>
  </reference>
  <reference>
    <citation>Tognetto D, Minutola D, Sanguinetti G, Ravalico G. Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study. Ophthalmology. 2005 Sep;112(9):1574.</citation>
    <PMID>16139666</PMID>
  </reference>
  <reference>
    <citation>Bhisitkul RB, Gonzalez VH. &quot;Heavy oil&quot; for intraocular tamponade in retinal detachment surgery. Br J Ophthalmol. 2005 Jun;89(6):649-50.</citation>
    <PMID>15923493</PMID>
  </reference>
  <reference>
    <citation>Wolf S, Schön V, Meier P, Wiedemann P. Silicone oil-RMN3 mixture (&quot;heavy silicone oil&quot;) as internal tamponade for complicated retinal detachment. Retina. 2003 Jun;23(3):335-42.</citation>
    <PMID>12824833</PMID>
  </reference>
  <reference>
    <citation>Rizzo S, Genovesi-Ebert F, Belting C, Vento A, Cresti F. A pilot study on the use of silicone oil-RMN3 as heavier-than-water endotamponade agent. Graefes Arch Clin Exp Ophthalmol. 2005 Nov;243(11):1153-7. Epub 2005 Jun 28.</citation>
    <PMID>15983817</PMID>
  </reference>
  <verification_date>November 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>June 28, 2009</last_update_submitted>
  <last_update_submitted_qc>June 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <keyword>Retinal detachment</keyword>
  <keyword>proliferative vitreoretinopathy</keyword>
  <keyword>heavier-than-water internal tamponades</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dissociative Disorders</mesh_term>
    <mesh_term>Retinal Detachment</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

